Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | XBP1 | P17861 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 5/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434222 | 1.00 | MEN1 (0.60) | MEN1NPC1HPGDRAB9AKMT2A | |
| SCHEMBL27521279 | 0.83 | MRGPRX4 (0.63) | MEN1KMT2ALMNAL3MBTL1MRGPRX4 | |
| SCHEMBL22874527 | 0.83 | EGFR (0.55) | MRGPRX4MAPTEGFRERBB2 | |
| SCHEMBL25648997 | 0.83 | EGFR (0.55) | MRGPRX4EGFRERBB2MAOB | |
| SCHEMBL24388658 | 0.81 | CYP1A2 (0.61) | MAPTEGFRERBB2MAOB | |
| SCHEMBL18805044 | 0.81 | MRGPRX4 (0.64) | MRGPRX4EGFRERBB2MAOB | |
| SCHEMBL156718 | 0.81 | MAOB (0.61) | MRGPRX4EGFRERBB2IDO1AGXT | |
| SCHEMBL5312817 | 0.81 | EGFR (0.54) | MRGPRX4EGFRERBB2MAOB | |
| SCHEMBL29514868 | 0.81 | MAOB (0.61) | MRGPRX4EGFRERBB2IDO1AGXT | |
| SCHEMBL3700337 | 0.81 | EGFR (0.54) | MRGPRX4EGFRERBB2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108524-A1 | EGFR INHIBITORS FOR TREATING LUNG CANCER | UNIV CALIFORNIA (US) | 2026-04-23 | — | — | US | claimed |
| WO-2024102177-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF BRAIN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-05-16 | — | — | WO | claimed |
| WO-2023244639-A1 | METHODS OF PREDICTING CNS CANCER RESPONSE TO TREATMENT WITH EGFR INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-12-21 | — | — | WO | claimed |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | claimed |
| CN-113811528-A | Compositions and methods for treating cancer | 加利福尼亚大学董事会 | 2021-12-17 | — | — | CN | claimed |
| CN-111868039-A | Compositions and methods for treating cancer | 加利福尼亚大学董事会 | 2020-10-30 | — | — | CN | claimed |
| US-20200290978-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-17 | — | — | US | claimed |
| US-20260108524-A1 | EGFR INHIBITORS FOR TREATING LUNG CANCER | UNIV CALIFORNIA (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4601652-A1 | EGFR INHIBITORS FOR TREATING LUNG CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250145634-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-05-08 | — | — | US | disclosed |
| WO-2024102177-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF BRAIN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024081447-A1 | EGFR INHIBITORS FOR TREATING LUNG CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20240043390-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-08 | — | — | US | disclosed |
| CN-111868039-A | Compositions and methods for treating cancer | 加利福尼亚大学董事会 | 2020-10-30 | — | — | CN | disclosed |
| US-20200290978-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3687981-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | The Regents of the University of California (US) | 2020-08-05 | — | — | EP | disclosed |
| WO-2019067543-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-04 | — | — | WO | disclosed |
| EP-1802633-A1 | BENZOTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | Bayer Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| EP-1294715-B1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | GLAXO GROUP LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| WO-2006044524-A1 | BENZOTHIENO’2,3-D! PYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE ACTIVITIES OF THE EPIDERMAL GROWTH FACTOR RECEPTORS (EGFRS) FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145634-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | MEN1 3431/4885NPC1 800/4885HPGD 1757/4885 |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | MEN1 3446/4885NPC1 834/4885HPGD 1603/4885 |
| US-20200290978-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | MEN1 3446/4885NPC1 834/4885HPGD 1603/4885 |
| US-20240043390-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | MEN1 3446/4885NPC1 834/4885HPGD 1603/4885 |
| US-20260108524-A1 | EGFR INHIBITORS FOR TREATING LUNG CANCER | EGFR, ERBB2, ERBB3 | MEN1 4341/4885NPC1 2979/4885HPGD 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.